BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...
Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...
During the ongoing government shutdown, ClinicalTrials.gov, the nation’s central registry for medical research and clinical ...
The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent ...
(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...
The first of two Black Book investor briefs identifies the health-tech categories demonstrating pilot-to-scale momentum and ...
Roseman University of Health Sciences and PDS Health® celebrated the dedication and ribbon-cutting of the new Thorne Clinic ...
The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback